Skip to Content

Pfizer -Eliquis (Apixaban) Available in the UK for the Prevention of Blood Clots After Elective Hip Or Knee Replacement

From ENP Newswire (September 21, 2011)

ENP Newswire - 21 September 2011

Release date- 20092011 - London - - The alliance of Bristol-Myers Squibb and Pfizer Ltd. announced today that apixaban, an oral treatment, is now available in the UK for the prevention of venous thromboembolic events (VTE - blood clots) in adult patients who have undergone elective total hip or knee replacement surgery.

'Blood clots are responsible for around 25,000 preventable deaths in the UK annually and preventing them following, for example, major joint surgery, is a priority for the NHS. Apixaban represents a new option in clot prevention for UK surgeons,' said Dr Ander Cohen, Honorary Consultant Vascular Physician at King's College Hospital, London.

'Apixaban is an oral option for patients once they return home after surgery - the time when they are most at risk of clotting complications. As it is taken by mouth, it offers patients an alternative to an injected anticoagulant.'

Dr Cohen continued: 'Clinical data showed that Apixaban was more effective than the anticoagulant enoxaparin and importantly, it also showed no increase in bleeding rates compared to enoxaparin.'

Professor Michael Rud Lassen, Glostrup Hospital in Copenhagen, Denmark, and lead investigator for the Phase 3 orthopaedic trials for apixaban said: 'The initiation of treatment after surgery is an option recommended in guidelines. Doctors have to consider the benefits of treatment before or after surgery against the risk of bleeding, which can be caused by anticoagulation. The first dose of apixaban is given 12-24 hours after surgery, which allows the doctor time to ensure bleeding has stopped.'

The licensing of apixaban is based on the ADVANCE-2 and ADVANCE-3 clinical trials in patients undergoing elective total hip or knee replacements.1,2 These trials included over 8,000 patients and assessed the efficacy (in preventing clotting and death) and bleeding risk of apixaban compared to enoxaparin.

'By making apixaban available to doctors and their patients in the UK - an important milestone for the Alliance - we hope to help reduce the burden of blood clots in patients undergoing elective hip and knee replacement,' said Dr Rick Lones, UK Executive Medical Director, Bristol-Myers Squibb.

[Editorial queries for this story should be sent to]

((Comments on this story may be sent to


Posted: September 2011